Tepotinib in Asian patients with METex14 skipping NSCLC
VISION, the largest study of a MET inhibitor for rare NSCLC with METex14 skipping mutations, shows tepotinib's efficacy and safety in Asian patients align with overall results. It provides the first health-related quality of life assessment for this group, supporting once-daily tepotinib treatment.